Pharmaceutical Industry
Filter News
Found 53,521 articles
-
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
1/4/2024
Innate Pharma SA announced that the U.S. Food and Drug Administration has lifted the partial clinical hold placed on the lacutamab IND.
-
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
1/4/2024
Innate Pharma SA announced that it has strengthened the Company’s leadership and corporate governance with the appointment of two new Executive Board members.
-
Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
1/4/2024
Longboard Pharmaceuticals, Inc. announced the pricing of an upsized underwritten public offering of 10,000,000 shares of its voting common stock at a price to the public of $21.00 per share.
-
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
1/4/2024
Keros Therapeutics, Inc. announced the pricing of an underwritten public offering of 3,500,000 shares of common stock, at a public offering price of $40.00 per share.
-
SELLAS Life Sciences Announces Proposed Public Offering - Jan 04, 2024
1/4/2024
SELLAS Life Sciences Group, Inc. announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of common stock in a public offering.
-
Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases
1/4/2024
Sitryx Therapeutics announces that Eli Lilly & Company has commenced a Phase 1 first-in-human study of SIT-011, a post-translational modification modulator program for chronic autoimmune and inflammatory diseases.
-
In a collaboration agreement announced Wednesday, Boehringer Ingelheim will gain access to Ribo’s platform to target hepatocytes with investigational siRNA therapies for nonalcoholic or metabolic dysfunction-associated steatohepatitis. -
The money will be funneled into early- to mid-stage therapeutic companies with “multi-asset portfolios” for the “next generation” of biotechs in addition to diagnostic and life sciences tools. -
2024 Predictions for Biotech M&As
1/3/2024
Continued fallout from the IRA, heightened antitrust enforcement and the rise of AI will all shape the first wave of biotech mergers and acquisitions coming this year, experts tell BioSpace. -
The regulator greenlit 55 new drugs last year, seven of which belonged to Pfizer, including an ulcerative colitis treatment and a migraine nasal spray—both acquired in multibillion-dollar buys. -
It wasn't a merry end to 2023 for Amgen or Zealand Pharma, which received Complete Response Letters for Lumakras and for dasiglucagon in congenital hyperinsulinism. -
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Karyopharm Therapeutics Inc. announced that the Company's senior management team will participate at the 42nd Annual J.P. Morgan Healthcare Conference in a podium presentation on Wednesday, January 10 at 2:15 p.m. PT, followed by a question-and-answer breakout session at 2:35 p.m. PT.
-
SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones
1/3/2024
SELLAS Life Sciences Group, Inc. provided a business update and will host a corporate webinar at 8:30 am ET.
-
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™
1/3/2024
Verrica Pharmaceuticals Inc., a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, announced that it is growing its distribution network by entering into an agreement with Walgreen Co. to distribute YCANTH™ through its specialty pharmacy.
-
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Atea Pharmaceuticals, Inc. announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 10:30 a.m. PT in San Francisco, CA.
-
BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
BioCryst Pharmaceuticals, Inc. announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024, at 6:00 p.m. ET.
-
XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease
1/3/2024
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces submission of a new patent for the treatment of chronic kidney disease.
-
Melt Pharmaceuticals Provides Corporate Update - Jan 03, 2024
1/3/2024
Melt Pharmaceuticals, Inc., a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, provided a corporate update.
-
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
1/3/2024
Agios Pharmaceuticals, Inc. announced that the global Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent alpha- or beta-thalassemia achieved its primary endpoint of hemoglobin response.
-
Alzheon CEO Dr. Martin Tolar to Present ALZ-801/Valiltramiprosate Investigational Oral Alzheimer’s Treatment Program at Nobel Forum at Karolinska Institute in Stockholm, Sweden
1/3/2024
Alzheon, Inc. announced its participation in the Nobel Forum “Challenges for Implementation of New Alzheimer’s Disease Treatments” covering Alzheimer’s therapeutics for the future, at the Karolinska Institute in Stockholm, Sweden from January 18-19.